fig5
Figure 5. Impact of RAS/PI3K signaling on radiotherapy response. Ionizing radiation activates the RAS/PI3K signaling pathway, resulting in downstream effects that promote MDR by enhancing DNA repair and stimulating the mevalonate pathway. The use of HDAC inhibitors, DNA-PK inhibitors, or statins to target key components of this axis holds promising potential when combined with radiotherapy. RAS: Rat sarcoma; PI3K: phosphoinositide 3-kinase; MDR: multidrug resistance; HDAC: histone deacetylase; DNA-PK: DNA-dependent protein kinase.
